SageView Advisory Group’s Denali Therapeutics DNLI Stock Holding History

SageView Advisory Group’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-25	Closed	-$413	–	1072
2025 Q4	$413	Buy	+25	New	+$422	﹤0.01%	2463

Other funds holding DNLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

SageView Advisory Group's DNLI Position: Q1 2026 in Review

SageView Advisory Group sold out of Denali Therapeutics (DNLI) in Q1 2026, closing a stake of 25 shares — an estimated $413 sold.

SageView Advisory Group first reported a position in DNLI in Q4 2025 and held it in 1 quarter. The position peaked at $413 in Q4 2025. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

SageView Advisory Group reported no remaining Denali Therapeutics position as of Q1 2026 after selling out during the quarter.
SageView Advisory Group sold 25 Denali Therapeutics shares in Q1 2026, an estimated $413.
SageView Advisory Group first reported a position in Denali Therapeutics in Q4 2025 and held it in 1 quarter.
SageView Advisory Group's Denali Therapeutics position peaked at $413 in Q4 2025.
269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.